Asahi Kasei Bioprocess America (AKBA) and PeptiSystems have announced a strategic, exclusive partnership aimed at delivering a streamlined process to the peptide manufacturing industry. This collaboration establishes AKBA as the exclusive OEM for peptide synthesis columns to PeptiSystems, which carries out R&D, manufacturing, and supply of instruments used to synthesize peptide and oligonucleotide therapeutics.
Asahi Kasei Bioprocess America is part of the Asahi Kasei Life Science operating segment, encompassing the organization’s purification, fluid management, biosafety, and biologics development and manufacturing divisions. The partnership combines AKBA’s industry knowledge and product expertise with PeptiSystems’ synthesizers. Asahi Kasei Bioprocess America will supply PeptiSystems, located in Uppsala, Sweden, with their patented THESYS ACS Ergo design, which will be optimized for peptide processing. Unveiled in 2024, this column offers reduced changeover time between batches without compromising user safety and product quality.
The partnership between Asahi Kasei Bioprocess America and PeptiSystems will extend globally across all relevant markets, such as drug and contract manufacturing. Based on flow-through chemistry and solid support, the companies anticipate this will bring evolutionary means for peptide processing to the industry and their customers.
This announcement closely follows a notice regarding the operational start of Asahi Kasei Life Sciences, under which the company’s bioprocess division will operate. In addition to Asahi Kasei Bioprocess America, Asahi Kasei Life Sciences includes Planova and Microfilters BioOptimal, its contract research organization (CRO) testing services performed by ViruSure of Austria, Bionique Testing Laboratories, and a biologics contract development and manufacturing organization (CDMO), Bionova Scientific.
